Naltrexone for Binge Eating: What You Track and Pass On

Medication	Evidence status	What the therapist tracks	What to pass on
Lisdexamfetamine	FDA-approved, adult moderate-severe BED	Binge days, sleep, jitter, missed doses	Binge-day change; stimulant effects
Naltrexone-bupropion	Weight-management label; BED off-label	Binge days, nausea, mood, opioid use	Frequency vs weight aim; any opioid
Naltrexone alone	AUD and opioid blockade; not BED	Cravings, nausea, opioid or pain meds	Off-label status; opioid exposure
Bupropion alone	Not for BED; AN/BN contraindicated	Mood, purge history, seizure talk	Prior AN/BN; binge vs purge

Jordan, 38, texts you on a Tuesday: the PCP started naltrexone-bupropion for “food noise,” and they want you to tell them if naltrexone for binge eating is the real treatment. You are not the prescriber. You still have a job. Count binge days, name side effects in the client’s words, keep the hour on interruption of bingeing rather than on pounds, and send a short observation to the person who can change the medication.

Count binge days, name side effects in the client’s words, keep the hour on interruption of bingeing rather than on pounds, and pass those observations to the medical clinician. For the hour that interrupts the binge, use eating disorder therapy techniques.

What naltrexone for binge eating actually is

Clients hear three different stories and mash them into one. Naltrexone blocks opioid receptors and is FDA-approved for alcohol use disorder and for blocking exogenously administered opioids. The naltrexone-bupropion tablet is FDA-approved, with diet and activity, for long-term weight management in adults with obesity or with overweight plus a weight-related condition. Neither label names binge-eating disorder. Lisdexamfetamine does: moderate to severe binge-eating disorder in adults, with an explicit limitation that it is not indicated for weight loss.

So when a client asks about naltrexone for binge eating, you are usually hearing one of four things: a PCP started the weight-management combination, an addiction clinician continued naltrexone after alcohol treatment and the bingeing is still there, a friend used the phrase “food addiction,” or someone saw Wellbutrin on a forum. Your first move is to name which medication is actually in the bottle, then match it to the row above.

Lisdexamfetamine

What the therapist tracks: Binge days per week, not pounds. Sleep, dry mouth, feeling jittery, anxiety, skipped meals that look like “the appetite is finally gone,” and any talk of sharing, running out early, or using someone else’s stimulant.

What to pass on: Whether binge days moved, in which direction, and which stimulant-class effects the client actually reported. The VYVANSE label is the FDA source for the adult BED indication, the boxed warning on abuse and misuse, and the limitation of use against weight-loss prescribing. You do not interpret that label into a dose. You tell the prescriber what changed in session.

Two 12-week randomized trials in adults with moderate to severe BED are what that indication sits on. If binge days are flat after a stretch the prescriber already named as a trial, say they are flat. The label’s “stop if binge eating does not improve” sentence is the prescriber’s decision, not a therapy homework item.

Naltrexone-bupropion

What the therapist tracks: Binge frequency separate from weight. Nausea, constipation, headache, insomnia, dry mouth. Mood, including new agitation or hopelessness. Any opioid, including postsurgical plans, cough syrups the client thinks of as harmless, and medication for alcohol or opioid use disorder.

What to pass on: Binge-day counts next to whether the client or the PCP is treating this as a weight-loss trial. The CONTRAVE label is the FDA source: naltrexone plus bupropion, indicated for weight management, not for BED, with a boxed warning on suicidal thinking and behavior related to the bupropion component, and a hard stop on opioid use. If an opioid appears, pass it the same day. Do not wait for the next med-check.

Grilo and colleagues (2022) in the American Journal of Psychiatry ran a 16-week 2×2 trial in 136 adults with BED and obesity: naltrexone-bupropion and behavioral weight-loss therapy, alone and combined. Binge-eating remission was 17.7% on placebo, 31.3% on naltrexone-bupropion, 37.1% on behavioral weight-loss therapy plus placebo, and 57.1% on the combination. Behavioral weight-loss therapy beat no behavioral weight-loss therapy. Naltrexone-bupropion beat placebo on remission. There was no significant interaction. A later pooled analysis of naltrexone-bupropion BED trials found no significant benefit over placebo on binge-eating frequency, which is why you report counts rather than a story that “the food-noise pill is working.”

Naltrexone alone

What the therapist tracks: Still binge days. Craving language. Nausea. And, again, opioids. A client on naltrexone for alcohol use disorder who starts talking about a dental procedure or leftover oxycodone is a coordination problem, not a curiosity.

What to pass on: That the client is asking about naltrexone for binge eating as if it were the BED drug, and that the bottle in front of them is the alcohol or opioid product. The oral naltrexone label is the FDA source: alcohol dependence and blockade of exogenously administered opioids. There is no BED indication. Name the gap. Let the prescriber decide whether a BED-indicated option, a weight-management combination, or no medication is the next medical step.

Bupropion alone

What the therapist tracks: Mood and activation, because that is often why the PCP reached for it. A careful binge versus purge history, including “I used to” and “only when I was younger.” Any seizure talk, head injury, abrupt alcohol cut-down, or extra bupropion from a second brand.

What to pass on: Current or prior anorexia nervosa or bulimia nervosa, in those words, the same day. The Wellbutrin XL label contraindicates those diagnoses because of a higher incidence of seizures. Binge-eating disorder is not listed there. That is not permission for you to bless Wellbutrin for BED. If a forum told the client that binge eating disorder Wellbutrin is “the other option,” correct the forum in session and send the history to the prescriber.

What you track every week

You need a number you can hand off. Binge days this week, binge episodes if the client can split them, and a one-line trigger (skipped lunch, evening collapse, conflict). The Binge Eating Scale is the scored companion when you want a repeated measure rather than a diary count. Do not replace the diary with a once-a-quarter scale and call it tracking.

Watch the therapy frame. If the client only wants to know what they weighed, the medication hour has eaten the treatment. Return to regular eating, urge surfing, and the chain that actually precedes a binge. Those techniques do not live on a label.

Symptoms requiring immediate medical or emergency assessment

Do not turn these reports into a medication recommendation. Follow your practice emergency process, arrange immediate medical or emergency assessment, and then document and coordinate with the prescriber.

• Chest pain, shortness of breath, or fainting while taking lisdexamfetamine
• Any reported seizure while taking bupropion
• A new head injury while taking bupropion: arrange prompt medical assessment rather than leaving a routine medication message; use emergency services when acute symptoms or immediate danger are present

Observations to send to the prescriber the same day

Use this tier when the client is otherwise stable and none of the immediate-assessment symptoms above are present. Send the observed or reported facts; do not advise a dose change.

• Any opioid exposure on a naltrexone product, including a planned procedure
• A resting pulse the client reports as newly fast on a stimulant, without chest pain, shortness of breath, or fainting
• Sharing, selling, or running out early of lisdexamfetamine
• Rapid restriction that the client describes as a medication success
• Active purging that was not in the history you sent

What you pass, and what you do not

Write observations. Do not write a suggested milligram. Do not write “consider increasing.” Do not interpret labs you have not seen. A useful pass-on is dated, names the medication the client reports, gives binge-day counts, lists side effects in the client’s words, flags opioids or misuse, and states the therapy goal in behavioral terms.

If the presentation is bulimia nervosa rather than BED, the PROZAC label is the FDA source: fluoxetine is indicated for binge-eating and vomiting behaviors in adults with moderate to severe bulimia nervosa. Send that medication map to Prozac for bulimia.

Keep eating-disorder-focused psychotherapy in the hour. Medication can sit beside that plan. It does not replace it, and it does not turn you into the prescriber.

Naltrexone for food addiction

Clients will keep using that phrase. You can translate it without adopting it. Loss of control, continued use despite harm, and craving around highly palatable food are binge-eating behaviors you already know how to count. They are not a second diagnosis you add so that naltrexone for binge eating sounds like alcohol treatment. If an addiction clinician is already prescribing naltrexone for alcohol use disorder, coordinate. Do not run a parallel “food addiction protocol” from a blog.

Keep the observation next to the note, not in a parallel spreadsheet you forget to send.

References